 |
|
|
|
|
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
BeyondSpring Pharmaceuticals
| | | | | Phone: | (646) 305-6387 | | Fax: | (646) 219-9660 | | Year Established: | 2013 | | Ticker: | BYSI | | Exchange: | NASDAQ | | Main Contact: | Lan Huang, Ph.D., Co-Founder, Chairman & CEO | | | | Other Contacts: | G. Kenneth Lloyd, Ph.D., CSO
Edward Dongheng Liu, CFO
Gordon L. Schooley, Ph.D., Chief Regulatory Officer
Ramon Mohanlal, M.D., Ph.D., M.B.A., CMO
Richard J. Daly, COO
| | | | Company Description | | BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market. | |
|
|
|
|
|
|
|
